Chronic idiopathic hyperphosphatasia: Normalization of bone turnover with cyclical intravenous pamidronate therapy

Bone

Volumn 35, Issue 1, 2004, Pages 210-216

  Tau, Cristina ^a,c   Mautalen, Carlos ^b   Casco, Cristina ^b   Alvarez, Verónica ^a   Rubinstein, Marta ^c  

^a Metabolismo Calcico Y Oseo   (Argentina)

^b Ctro de Osteopatias Medicas   (Argentina)

^c HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Alkaline phosphatase; Bisphosphonates; Juvenile Paget disease; Urinary CTX

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; HYDROXYPROLINE; PAMIDRONIC ACID; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BONE DEVELOPMENT; BONE DISEASE; BONE MALFORMATION; BONE MARROW BIOPSY; BONE TURNOVER; CASE REPORT; CELL ACTIVITY; CHILD; CHRONIC DISEASE; CHRONIC IDIOPATHIC HYPERPHOSPHATASIA; CLINICAL FEATURE; CRANIAL NERVE; DEVELOPMENTAL DISORDER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FEMALE; FRACTURE; GAIT DISORDER; HAIR GROWTH; HEARING LOSS; HUMAN; HYDROXYPROLINE URINE LEVEL; KYPHOSCOLIOSIS; LABORATORY TEST; LIMB DEFORMITY; LONG BONE; LORDOSIS; LUMBAR VERTEBRA; MASTOID; OSTEOCLAST; SCLEROSIS; SHORT STATURE; SKULL; TOOTH ERUPTION; TREATMENT OUTCOME; VALGUS KNEE;

ADMINISTRATION, ORAL; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CHILD; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAVENOUS; OSTEITIS DEFORMANS;

EID: 2942718818     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.03.013     Document Type: Article

References (33)

1. Bianchi M.L., Cimaz R., Bardare M., Zulian F., Lepore L., Boncompagni A., et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children. Arthritis Rheum. 43:2000;1960-1966
2. Blanco O., Stivel M., Mautalen C.A., Schajowicz F. Familial idiopathic hyperphosphatasia. A study of two young siblings treated with porcine calcitonin. J. Bone J. Surg. 59:1977;421-427
3. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:1995;864-868
4. Caffey J. Familial hyperphosphatasemia with ateliosis and hypermetabolism of growing membranous bone; review of the clinical, radiographic and chemical features. Prog. Pediatr. Radiol. 4:1973;438-468
5. Cassinelli H.R., Mautalen C.A., Heinrinch J.J., Miglietta A., Bergada C. Familial hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone Mineral. 19:1992;175-184
6. Demir E., Bereket A., Ozkan B., Topçu M. Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J. Pediatr. Endocrinol. Metab. 13:2000;217-221
7. Doyle F.H., Woodhouse N.J.Y., Glen A.C.A., Joplin G.F., MacIntyre I. Healing of the bones in juvenile Paget's disease treated by human calcitonin. Br. J. Radiol. 47:1974;9-15
8. Dunn V., Condon V.R., Rallison M.L. Familial hyperphosphatasia: diagnosis in early infancy and response to human thyrocalcitonin therapy. Am. J. Roentgenol. 132:1979;541-545
9. Eyring E.J., Eisenberg E. Congenital hyperphosphatasia: a clinical, pathological and biochemical study of two cases. Bone J. Surg. Am. 50:1968;1099-1117
10. Fanconi G., Moreira G., Uehlinger E., Giedion A. Osteochalasia desmalis familiaris: hyperostosis corticalis deformans juvenilis, chronic idiopathic hyperphosphatasia osteoectasia and macrocranium. Helv. Paediatr. Acta. 19:1964;279-295
11. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339:1998;947-952
12. Hoekman K., Papapoulos S.E., Peters A.C., Bijvoet O.I. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J. Clin. Endocrinol. Metab. 61:1985;952-956
13. Horwith M., Nunez E.A., Krook L., Viteri F., Torun B., Mena E., et al. Hereditary bone dysplasia with hyperphosphatasia: response to synthetic human calcitonin. Clin. Endocrinol. 5:1976;341s-352s. [Suppl.]
14. Iancu T., Almagor G., Friedman E., Hardoff R., Front D. Chronic familial hyperphosphatasemia. Radiology. 129:1978;669-676
15. Kiviricko K.I., Laitinen O., Prockop E.J. Modifications of a specific assay for hydroxyprolyne in urine. Anal. Biochem. 19:1967;249-255
16. Kruse K. Normal bone turnover in isolated hyperphosphatasemia. J. Pediatr. 106:1985;946-948
17. Kutluk M.T., Hazar V., Akyü C., Varan A., Büyü kpamukçu M. Childhood cancer and hypercalcemia: report of a case treated with pamidronate. J. Pediatr. 130:1997;828-831
18. Lejarraga H., Orfila G. Estandares de Peso y Estatura para Niñas y Niños Argentinos desde el nacimiento hasta la madurez. Arch. Argent. Pediatr. 85:1987;209-222
19. Lteif A.N., Zimmermann D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 102:1998;990-993
20. McKusick V.A. Hyperostosis corticalis deformans juvenilis (Juvenile Paget Disease; chronic congenital idiopathic hyperphosphatasemia; familial osteoectasia). McKusick V.A. Mendelian inheritance in man. Catalogs of autosomal dominant, autosomal recessive, and X-linked phenotypes. seventh ed. 1986;1045-1046 The John Hopkins Univ. Press, Baltimore, MD
21. McNulty J., Pim P. Hyperphosphatasia. Am. J. Roentgenol. Radium Ther. Nucl. Med. 115:1972;614-618
22. Rauch F., Middelmann B., Cagnoli M., Keller K.M., Schonau E. Comparison of total alkaline phosphatase in childhood and adolescence. Acta Pædiatr. 86:1997;583-587
23. Shaw N.J., Boivin C.M., Crabtree N.J. Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 83:2000;143-145
24. Sidney B., Rosalk L., Ying Foo A. Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzimes in plasma. Clin. Chem. 30:1984;1182-1186
25. Silve C. Hypophosphatasie et hyperphosphatasie. Garabedian M., David L., Dumas R., Mallet E. Metabolisme phosphocalcique normal et pathologique chez l'enfant. 1993;162-166 Medecine-Sciences, Flammarion
26. Singer F., Siris E., Shane E., Dempster D., Lindsay R., Parisien M. Hereditary hyperphosphatasia: 20 years follow-up and response to disodium etidronate. J. Bone Miner. Res. 9:1994;733-738
27. Soubervielle J.C., Leger J., Guibourdanche J., Bonnet P., Herviaux P., Rigault M.Y., et al. Normative pediatric values for urinary CTX. J. Bone Miner. Res. 12:1997;S519. [Suppl.]
28. Thompson R.C. Jr., Gaull G.E., Horwitz S.J., Schenk R.K. Hereditary hyperphosphatasia. Am. J. Med. 47:1969;209-219
29. Tüysüz B., Mercimek ß., Üngür S., Deniz M. Calcitonin treatment in osteoectasia with hyperphosphatasia (Juvenile Paget's disease): radiographic changes after treatment. Pediatr. Radiol. 29:1999;838-841
30. Whalen J.P., Horwith M., Krook L., et al. Calcitonin treatment in hereditary bone dysplasia with hyperphosphatasia: radiographic and histologic study of bone. Am. J. Roentgenol. 129:1977;29-35
31. Whyte M.P., Obrecht S.E., Finnegan P.M., Jones J.L., Podgornik M.N., McAlister W.H., et al. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 347:2002;175-184
32. Woodhouse N.J.Y., Fisher M.T., Sigurdsson G., Joplin G.F., MacIntyre I. Paget's disease in a 5-year -old: acute response to human calcitonin. Br. Med. J. 4:1972;267-269
33. Zeghoud F., Jardel A., Guillozo H., N'Guyen T.M., Garabedian M. Micromethod for the determination of 25-hydroxyvitamin D. Norman A.W., Bouillon R., Thomasset M. Vitamin D: gene regulation, structure-function analysis and clinical application. 1991;662-663 Walter de Gruyter & Co. New York